Vaccine immunotherapy for immune suppressed patients
CA 2464228 C · Owner: Immuno-Rx, Inc. · Inventors: Hadden, John W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally a method for unblocking , immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 26, 2001 and granted January 17, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 26, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 26, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.